SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (231)7/23/1999 11:46:00 AM
From: Vector1  Read Replies (1) of 666
 
David,
Eric ENde, of Lehman, who is a major IDPH bull issued a report today projecting Bexxar year 3 sales at almost $300m. The report is based on Rutuxan keeping a dominant first line share and Bexxar being limited to salvage therapy. However, Eric believes that Bexxar will be premium priced at $12,500 a patient. He believes that HAMA response and bone marrow toxicity will keep Bexxar from becoming a first line therapy. He is wrong.

V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News